{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T19:14:25Z","timestamp":1760382865259,"version":"3.40.5"},"reference-count":14,"publisher":"JLE","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.nephro.2020.09.007","type":"journal-article","created":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T19:30:44Z","timestamp":1610479844000},"page":"53-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["A case of dasatinib-induced focal segmental glomerulosclerosis in a patient with Philadelphia chromosome positive chronic myeloid leukemia"],"prefix":"10.1684","volume":"17","author":[{"given":"Ezgi","family":"Ersoy Yesil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1954-9784","authenticated-orcid":false,"given":"Dede","family":"Sit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasan","family":"Kayabasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"Zerenler Gursoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa Behcet","family":"Demirbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibel","family":"Ocak Serin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2020.09.007_bib0005","series-title":"Comprehensive clinical nephrology","first-page":"218","author":"Johnson","year":"2015"},{"key":"10.1016\/j.nephro.2020.09.007_bib0010","doi-asserted-by":"crossref","first-page":"626","DOI":"10.2215\/CJN.05810513","article-title":"Glomerular diseases: FSGS","volume":"9","author":"Bose","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2020.09.007_bib0015","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/ajh.23282","article-title":"Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management","volume":"87","author":"Jabbour","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.nephro.2020.09.007_bib0020","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11523-015-0368-7","article-title":"Renal toxicities of targeted therapies","volume":"10","author":"Abbas","year":"2015","journal-title":"Target Oncol"},{"key":"10.1016\/j.nephro.2020.09.007_bib0025","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MD.0000000000000207","article-title":"Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single centre","volume":"93","author":"Izzedine","year":"2014","journal-title":"Medicine"},{"key":"10.1016\/j.nephro.2020.09.007_bib0030","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12882-019-1273-6","article-title":"Dasatinib-induced nephrotic syndrome in a patient with chronic myelogenous leukemia: a case report","volume":"20","author":"Ochiai","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nephro.2020.09.007_bib0035","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1172\/JCI17423","article-title":"Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases","volume":"111","author":"Eremina","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nephro.2020.09.007_bib0040","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/s41419-018-0878-1","article-title":"Nuclear YAP localisation as a key regulator of podocyte function","volume":"9","author":"Bonse","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.nephro.2020.09.007_bib0045","doi-asserted-by":"crossref","first-page":"6232","DOI":"10.1158\/1078-0432.CCR-09-0224","article-title":"Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumours","volume":"15","author":"Demetri","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nephro.2020.09.007_bib0050","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3349\/ymj.2016.57.2.532","article-title":"A case of dasatinib-induced nephrotic syndrome in a child with Philadelphia chromosome positive acute lymphoblastic leukemia","volume":"57","author":"Lim","year":"2016","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.nephro.2020.09.007_bib0055","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/s41467-019-09936-x","article-title":"Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity","volume":"10","author":"Calizo","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.nephro.2020.09.007_bib0060","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1053\/j.ajkd.2013.01.022","article-title":"Dasatinib-induced nephrotic-range proteinuria","volume":"61","author":"Wallace","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2020.09.007_bib0065","first-page":"70","article-title":"Cancer treatment-induced nephrotoxicity: BCR-Abl and VEGF inhibitors","volume":"50","author":"Rollino","year":"2010","journal-title":"G Ital Nefrol"},{"key":"10.1016\/j.nephro.2020.09.007_bib0070","first-page":"428","article-title":"Nephrotic syndrome under treatment with dasatinib: be aware of a possible adverse drug reaction","volume":"75","author":"Muller-Hansma","year":"2017","journal-title":"Neth J Med"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725520303850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725520303850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2020.09.007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:11:01Z","timestamp":1741191061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725520303850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1769725520303850"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2020.09.007","relation":{},"ISSN":["1769-7255"],"issn-type":[{"type":"print","value":"1769-7255"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A case of dasatinib-induced focal segmental glomerulosclerosis in a patient with Philadelphia chromosome positive chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2020.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 francophone de n\u00e9phrologie, dialyse et transplantation. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}